Telehealth Groups May Improve the Social Lives of Young Cancer Populations
Most patients with cancer who took part in a telehealth group expressed that they liked the members of their group and felt less social isolation.
Developers Terminate Clinical Program for Ociperlimab in Lung Cancer
A futility analysis showed that ociperlimab was unlikely to reach the primary end point of overall survival as part of the phase 3 AdvanTIG-302 trial.
Ensuring Ancillary Care Access to Bolster QOL in Pancreatic Cancer
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
PIPAC-MMC Shows Efficacy in Multiple Response Criteria for Peritoneal Mets
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
EU’s CHMP Recommends Approving Perioperative Nivolumab Combo in NSCLC
Data from the phase 3 CheckMate 77T trial support the CHMP’s opinion on approving the perioperative nivolumab regimen for those with resectable NSCLC.
Immunotherapy Plus Transplantation Improves Outcomes in Relapsed Lymphoma
“Recognizing that we could follow immunotherapy with a bone marrow transplant safely was quite important,” Nina Wagner-Johnston, MD, stated.
Peritoneal Tumor Treatment Enhanced by Pre-PIPAC-MMC Small Incision Surgery
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Guideline Update Supports Laser Therapy for Brain Tumors After SRS
The REMASTer trial found that laser interstitial thermal therapy was equivalent to open craniotomy regarding OS and PFS data in progressive metastatic brain tumors.
A Staged Approach Offers Benefits Without OS Detriment in Appendix Cancers
Muhammad Talwa Waheed, MD, found that resection after appendectomy should be prioritized in the treatment of patients with appendiceal cancer.
Relacorilant/Chemo Show Survival Benefit in Platinum-Resistant Ovarian Cancer
The phase 3 ROSELLA trial results assessing relacorliant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.
EU’s CHMP Has Positive Opinion for Subcutaneous Nivolumab in Solid Tumors
Data from the phase 3 CheckMate-67T trial support the CHMP’s recommendation for approving subcutaneous nivolumab across various solid tumor indications.
Intraperitoneal Therapy Seeks to Address “Nihilism” Around Peritoneal Mets
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
CHMP Grants Positive Opinion to Tislelizumab/Chemo in Front-Line ES-SCLC
Tislelizumab plus chemotherapy demonstrated superior OS, PFS, ORR, and DOR results compared with placebo plus chemotherapy in first-line ES-SCLC.
AI, Immunotherapy, More Key Lung Cancer Advances Highlighted at 2025 ELCC
An expert panel at ELCC 2025 reviews the MARIPOSA trial's implications for first-line therapy in EGFR-mutated NSCLC and broader advancements.
Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer
A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.
Talquetamab Elicits Sustained Responses in Pre-Treated R/R Multiple Myeloma
Cytokine release syndrome events primarily occurred during step-up and the first full dosing cycle in patients with relapsed/refractory multiple myeloma.
Solnerstotug Shows Promising Preliminary Data in PD-L1 Resistant Tumors
No dose-limiting toxicities were seen with solnerstotug in patients with PD-L1–resistant tumors, and most adverse effects were grades 1/2 in severity.
Theranostics and Radiopharmaceutical Use May Enhance Cancer Care
Greater cancer treatment longevity enables oncologists the ability to form more impactful relationships with their patients.
Episode 4: Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer
HIPEC Does Not Add Benefit to Cytoreduction Surgery in CRC Peritoneal Metastasis
Muhammed Talha Waheed, MD, stated that a retrospective study found an OS benefit in CRC peritoneal metastasis with cytoreduction surgery without HIPEC vs with HIPEC.
PIPAC-MMC Plus FOLFIRI Shows Feasibility, Safety in Peritoneal Metastases
Laparoscopic, histologic, and biomarker responses occurred at all dose levels of mitomycin treatment in patients with peritoneal metastases.
Local Excision After Chemo Achieves Negative Margins in Rectal Cancer
A phase 2 trial presented at SSO met its primary end point by achieving negative margins in 79% of patients with node-negative rectal cancer.
CHMP Recommends Acalabrutinib Combo Approval in Untreated MCL
Results from the phase 3 ECHO trial showed PFS and OS improvements with acalabrutinib in the first-line treatment of MCL compared with standard of care.
Sirexatamab Combo Shows Positive Activity in Advanced MSS Colorectal Cancer
Sirexatamab plus bevacizumab/chemotherapy significantly improved overall response rate in patients with high DKK1 levels in the phase 2 DeFianCe study.
Improving NSCLC Surgery Recovery After Climate Disaster Exposure
The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.
Exploring Novel Treatment Developments in Radiation Oncology
Adaptive radiation may help individualize therapy based on transient factors patients are faced with while receiving treatment for cancer.
Optimizing Opportunities to Deliver Personalized Radiation Oncology Care
Experts from Sibley Memorial Hospital highlight radiation oncology technologies that have played key roles in cancer care at their institution.
Osimertinib Shows Sustained Survival Benefit in EGFR-Mutant NSCLC
The safety profiles of osimertinib monotherapy and combination therapy were consistent with prior reports in EGFR-mutated non–small cell lung cancer.
Integrating Lorlatinib Into First-Line ALK-Positive NSCLC Treatment
Findings from the phase 3 CROWN trial evaluating lorlatinib in ALK-positive non–small cell lung cancer revealed a sustained PFS benefit with the agent.
Studying How Climate Disaster Responses Impact Post-NSCLC Surgery Survival
Future work may focus on determining strategies for protecting the health of patients who undergo surgery during climate disasters.
